Rigel Pharmaceuticals shareholders approve amended 2018 equity incentive plan

• Rigel Pharmaceuticals held its annual shareholder meeting on May 14, 2026.
• Stockholders adopted an amendment to the 2018 Equity Incentive Plan, increasing the share pool by 500,000 shares; the amended plan became effective immediately upon shareholder approval.
• An amendment to the 2000 Employee Stock Purchase Plan was also adopted, adding 360,000 shares; the amended plan became effective immediately upon shareholder approval.
• Stockholders ratified Ernst & Young as the company’s independent registered public accounting firm for the fiscal year ending Dec. 31, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rigel Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001034842-26-000041), on May 20, 2026, and is solely responsible for the information contained therein.